• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » How Medtronic designed the next generation of GI bleeding treatment

How Medtronic designed the next generation of GI bleeding treatment

September 29, 2022 By Sean Whooley

Medtronic nexpowder endoscopic hemostasis-system gastrointestinal gi bleeding
The Nexpowder system for treating GI bleeding. [Image courtesy of Medtronic]
Dr. Austin Chiang at Medtronic says there are plenty of ways to treat gastrointestinal (GI) bleeding. Cauterizing wounds — treating with heat — is one, while clipping the bleed to stop it is another.

However, Medtronic (NYSE:MDT) now offers a new way that Chiang thinks just might trump them all.

The company believes its newly FDA-cleared Nexpowder endoscopic hemostasis system is the future of GI bleeding treatment.

“It’s really innovative,” Chiang, CMO of the Gastrointestinal business at Medtronic, told MassDevice in a recent interview. “It addresses a lot of the shortcomings of existing technology out there.”

What is Medtronic’s Nexpowder?

Nexpowder is a noncontact, nonthermal and nontraumatic hemostatic powder sprayed through a catheter into the GI tract. It features a proprietary powder-coating technology. Medtronic designed it to minimize catheter clogging and particle scattering without requiring carbon dioxide or air compressors.

Chiang said the spray-on powder differentiates from other offerings on the market because it reacts to moisture, not just blood. It turns into a gel that’s adhesive, sticking to the bleeding area and allowing it to heal. This reaction to moisture also means it can be used in other applications.

“With existing systems out there, sometimes these powders get in the way to clog up the machine and clog up the device or inhibit your visualization,” Chiang said. “Our device actually is a very targeted type of powder. It’s easy to control and use and it doesn’t clog up the system.”

According to Medtronic, Nexpowder features a 94% immediate hemostasis rate. It comes in at two times the adhesive force of other hemostatic sprays, the company said, and it contributes to a mere 3.7% rebleeding rate.

How Nexpowder works

Doctor Dr. Austin Chiang, CMO of the Gastrointestinal business at Medtronic
Dr. Austin Chiang, CMO of the Gastrointestinal business at Medtronic [Image from Chiang’s LinkedIn page]
The device features a handle attached to a catheter that is fed down a scope channel. That channel leads down to, for instance, an ulcer or bleeding lesion in the stomach. Chiang then said the person performing the endoscopy directly turns on the spray handle for the device and applies the powder. It delivers the powder in what he described as a motorized fashion, through the catheter onto the target lesion.

Chiang said the targeted delivery factor distinguishes Nexpowder from the rest of the market. He said that, historically, a problem has been a “scattered cloud” of powder, rather than direct delivery to the target. The reaction to moisture represents another advantage, he said.

The system features a blue gel to provide confidence that a lesion is fully covered. Additionally, the gel remains blue to simplify follow-up endoscopy.

Altogether, Chiang said the visualization aspect of Medtronic’s technology is another step forward.

“The visualization, because it’s targeted, allows us to actually see what we’re doing,” Chiang explained. “You can imagine, if it’s just a big cloud of powder, you can’t really see through that. It’s actually something that we’ve run into in the past with other systems.”

Adding to the GI portfolio

Nexpowder effectively rounds out the Medtronic gastrointestinal portfolio, which features the GI Genius for detecting colorectal polyps through enhanced visualization during colonoscopy.

The portfolio stretches across the stages of GI treatment, Chiang said, with Nexpowder fitting in as something of a final puzzle piece.

“I think [Nexpowder is] important,” Chiang said. “Our vision is really to cover the entire care continuum, and that means detection, resection and also protection. So, if we think about our portfolio, we have GI Genius, which is the kind of first-to-market AI polyp detection device that kind of serves as the detection piece of it. Then, resection is for bigger polyps that may need to be removed. We have tools that are also going to be commercialized very soon that are cleared by the FDA. And then, of course, this is the protection piece of it.

“We want to make sure that we see all of our patients through this entire spectrum.”

Filed Under: Business/Financial News, Catheters, Endoscopic, Featured, News Well Tagged With: Medtronic

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy